Kelsey Moore
Overview
Explore the profile of Kelsey Moore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
215
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gensemer C, Beck T, Guo L, Petrucci T, Morningstar J, Kornblau I, et al.
Res Sq
. 2024 Jul;
PMID: 38947032
Hypermobile Ehlers-Danlos syndrome (hEDS) is a common heritable connective tissue disorder that lacks a known genetic etiology. To identify genetic contributions to hEDS, whole exome sequencing was performed on families...
2.
Dinizulu S, Velez G, Morency M, Jacobson K, Moore K, Carter N, et al.
Prev Sci
. 2023 Sep;
25(1):68-84.
PMID: 37768423
This study reports on the feasibility and acceptability of a social justice infused service-learning (S-L) program to promote Black adolescent mental health and educational equity. We convened a community advisory...
3.
Luciani M, Montalbano M, Troncone L, Bacchin C, Uchida K, Daniele G, et al.
Eur Heart J
. 2023 May;
44(17):1560-1570.
PMID: 37122097
Background: Amyloid plaques and neurofibrillary tangles, the molecular lesions that characterize Alzheimer's disease (AD) and other forms of dementia, are emerging as determinants of proteinopathies 'beyond the brain'. This study...
4.
Beck T, Arhontoulis D, Morningstar J, Hyams N, Stoddard A, Springs K, et al.
JACC CardioOncol
. 2022 Nov;
4(4):535-548.
PMID: 36444237
Background: Trametinib is a MEK1 (mitogen-activated extracellular signal-related kinase kinase 1) inhibitor used in the treatment of BRAF (rapid accelerated fibrosarcoma B-type)-mutated metastatic melanoma. Roughly 11% of patients develop cardiomyopathy...
5.
Beck T, Springs K, Morningstar J, Mills C, Stoddard A, Guo L, et al.
Molecules
. 2022 Jun;
27(12).
PMID: 35744803
Cancer is the second most common cause of death in the United States, accounting for 602,350 deaths in 2020. Cancer-related death rates have declined by 27% over the past two...
6.
Morningstar J, Gensemer C, Moore R, Fulmer D, Beck T, Wang C, et al.
J Am Heart Assoc
. 2021 Dec;
10(24):e022332.
PMID: 34873924
Background Mitral valve prolapse (MVP) is one of the most common forms of cardiac valve disease and affects 2% to 3% of the population. Previous imaging reports have indicated that...
7.
Guo L, Beck T, Fulmer D, Ramos-Ortiz S, Glover J, Wang C, et al.
Dev Dyn
. 2021 Apr;
250(10):1432-1449.
PMID: 33811421
Background: Mitral valve prolapse (MVP) is a common and progressive cardiovascular disease with developmental origins. How developmental errors contribute to disease pathogenesis are not well understood. Results: A multimeric complex...
8.
Moore K, Fulmer D, Guo L, Koren N, Glover J, Moore R, et al.
J Cardiovasc Dev Dis
. 2021 Apr;
8(3).
PMID: 33805717
Mitral valve prolapse (MVP) is a common form of valve disease and can lead to serious secondary complications. The recent identification of MVP causal mutations in primary cilia-related genes has...
9.
Guo L, Glover J, Risner A, Wang C, Fulmer D, Moore K, et al.
J Cardiovasc Dev Dis
. 2020 Aug;
7(3).
PMID: 32824435
β-catenin has been widely studied in many animal and organ systems across evolution, and gain or loss of function has been linked to a number of human diseases. Yet fundamental...
10.
Fulmer D, Toomer K, Glover J, Guo L, Moore K, Moore R, et al.
Dev Biol
. 2020 Mar;
463(1):26-38.
PMID: 32151560
Non-syndromic mitral valve prolapse (MVP) is the most common heart valve disease affecting 2.4% of the population. Recent studies have identified genetic defects in primary cilia as causative to MVP,...